CA2562391A1 — Solid pharmaceutical preparation
Assigned to Takeda Pharmaceutical Co Ltd · Expires 2005-10-27 · 21y expired
What this patent protects
A solid pharmaceutical preparation which contains an insulin resistance reducer and an active ingredient (which is not an insulin resistance reducer). The insulin resistance reducer in this preparation shows an in vivo elution behavior which is similar to the elution behavior of…
USPTO Abstract
A solid pharmaceutical preparation which contains an insulin resistance reducer and an active ingredient (which is not an insulin resistance reducer). The insulin resistance reducer in this preparation shows an in vivo elution behavior which is similar to the elution behavior of the insulin resistance reducer in a "solid pharmaceutical preparation containing an insulin resistance reducer as the only active ingredient." The solid pharmaceutical preparation comprises (1) a layer containing an insulin resistance reducer and (2) a layer comprising (a) an active ingredient (which is not an insulin resistance reducer), (b) crystalline cellulose having an average particle diameter of 5-25 µm, (c) crystalline cellulose having an average particle diameter of 30-100 µm, and (d) polyvinylpyrrolidone K-90.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.